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Peptides synthesized in endocrine cells in the gastrointestinal tract and neurons are
traditionally considered regulators of metabolism, energy intake, and appetite. However,
recent work has demonstrated that many of these peptides act on corticostriatal-limbic
circuitry and, in turn, regulate addictive behaviors. Given that alcohol is a source of energy
and an addictive substance, it is not surprising that increasing evidence supports a role for
gut-brain peptides specifically in alcohol use disorders (AUD). In this review, we discuss
the effects of several gut-brain peptides on alcohol-related behaviors and the potential
mechanisms by which these gut-brain peptides may interfere with alcohol-induced
changes in corticostriatal-limbic circuitry. This review provides a summary of current
knowledge on gut-brain peptides focusing on five peptides: neurotensin, glucagon-like
peptide 1, ghrelin, substance P, and neuropeptide Y. Our review will be helpful to develop
novel therapeutic targets for AUD.
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INTRODUCTION
GUT-BRAIN PEPTIDES CONTROL FOOD AND ALCOHOL INTAKE
Peptides secreted by endocrine cells and enteric neurons in the
gastrointestinal (GI) tract and neurons in the central nervous
system (CNS), have been implicated in the pathophysiology of
alcohol use disorders (AUD). Gut-brain peptides have differ-
ent functions when administered into the brain relative to the
periphery since the blood-brain barrier (BBB) restricts access of
peripheral peptides to the CNS. In addition, gut-brain peptides
typically have a short half-life due to rapid inactivation by pepti-
dases. Although gut-brain peptides have numerous site-specific
functions, they are generally considered to act as regulators of
energy intake and expenditure. Alcohol is both an addictive
Abbreviations: a.a., amino-acid; AA, alcohol-accepting; ANA, alcohol-non-
accepting; AUD, alcohol use disorder; BBB, blood-brain barrier; CeA, central
nucleus of the amygdala; CNS, central nervous system; CPP, conditioned place
preference; CREB, cAMP response element-binding protein; D2R, dopamine D2
receptor; DLS, dorsolateral; DMS, dorsomedial; DPP-4, dipeptidyl peptidase-4;
Ex4, exendin-4, fMRI, functional magnetic resonance imaging; GHS-R1a, growth
hormone secretagogue receptor 1a; GI, gastrointestinal; GLP-1, glucagon-like pep-
tide 1; GLP-1R, glucagon-like peptide 1 receptor; GOAT, ghrelin O-acyltransferase;
HAD, high-alcohol-preferring; HPA, hypothalamic-adrenal-pituitary; LAD, low-
alcohol-preferring; LDTg, laterodorsal tegmental area; LS, long-sleep; MSNs,
medium spiny neurons; NAc, nucleus accumbens; NK1R, neurokinin 1 receptor;
NK2R, neurokinin 2 receptor; NK3R, neurokinin 3 receptor; NP, alcohol-non-
preferring; NPY, neuropeptide Y; NT, neurotensin; NTS1, neurotensin receptor
type 1; NTS2, neurotensin receptor type 2; OCDS, Obsessive Compulsive Drinking
Scale; P, alcohol-preferring; PACS, Pennsylvania Alcohol Craving Scores; PFC, pre-
frontal cortex; QTL, quantitative trait loci; REM, rapid eye movement sleep; SN,
substantia nigra; SNPs, single-nucleotide polymorphisms; SP, substance P; SS,
short-sleep; WHP, Warsaw high-preferring; WLP, Warsaw low-preferring; VTA,
ventral tegmental area.
substance and a source of energy. Therefore, it is not surprising
that there are peptidergic signaling links between appetitive- and
alcohol-related behaviors.
There are numerous lines of evidence indicating a mechanis-
tic link between alcohol drinking and food intake. For example,
there is a high comorbidity between AUD and eating disor-
ders, especially bulimia (Goldbloom et al., 1992; Dansky et al.,
2000; Bulik et al., 2004). Interestingly, many approved and exper-
imental treatments for AUD (including naltrexone, disulfiram,
baclofen, and varenicline) suppress appetite and reduce body
weight (Leggio et al., 2011). Furthermore, the hedonic response
to sucrose in humans was shown to associate with parental his-
tory of AUD, suggesting that hedonic response to sucrose may
indicate a genetic risk for AUD (Kampov-Polevoy et al., 2001,
2003). Sweet preference is partially regulated by gut-brain pep-
tide signaling in the brain. Thus, the same gut-brain peptides that
regulate hedonic food intake may also affect alcohol consumption
(Furudono et al., 2006; Skibicka et al., 2011). As discussed in this
review, many gut-brain peptides and their receptors are expressed
within corticostriatal-limbic circuitry. Since there is overlapping
corticostriatal-limbic circuitry that regulates food intake and
alcohol consumption (Volkow et al., 2009, 2012b; Kenny, 2011), it
is not surprising that some orexigenic peptides (ghrelin) increase
(Schneider et al., 2007; Jerlhag et al., 2009) and some anorexigenic
peptides [neurotensin, glucagon-like peptide 1 (GLP-1)] decrease
alcohol consumption (Lee et al., 2010; Egecioglu et al., 2012).
However, alcohol has direct pharmacological effects on neurons
that differ from the effects of palatable food intake, which may
explain why there are also examples of gut-brain peptides [e.g.,
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neuropeptide Y (NPY)] that exhibit opposite effects on feeding
and alcohol drinking (Thorsell et al., 2005a).
CORTICOSTRIATAL-LIMBIC CIRCUITRY AND AUD
Many gut-brain peptides and/or their receptors are found in
corticostriatal-limbic circuitry, where alcohol-induced maladap-
tations are thought to underlie the behaviors associated with
AUD (Binder et al., 2001a; Korotkova et al., 2003; Herpfer and
Lieb, 2005; Dickson et al., 2011; Volkow et al., 2012a; Egecioglu
et al., 2013; Shirazi et al., 2013). As shown in Figure 1A, the
nucleus accumbens (NAc, part of the ventral striatum) and dor-
sal striatum receive glutamatergic projections from the cortex.
However, the NAc also receives glutamatergic projections from
the hippocampus and amygdala. Dopaminergic afferents from the
ventral tegmental area (VTA) in the midbrain project largely to
the NAc (mesolimbic pathway), while the substantia nigra (SN)
pars compacta is the main source of dopamine in the dorsal stria-
tum (nigrostriatal pathway). GABAergic medium spiny neurons
(MSNs) in the striatum are the primary output neurons that
are typically quiescent. When these neurons are activated, they
tend to inhibit the tonically active pallidum, which contains pri-
marily GABAergic neurons (Graybiel, 2000). Therefore, MSNs in
this “direct pathway” or striatonigral pathway disinhibit thalam-
ocortical targets, which facilitates movement and possibly drug
seeking. In contrast, MSNs in the “indirect pathway” or the stri-
atopallidal pathway inhibit downstream thalamocortical targets
and activation of this pathway may suppress certain behaviors
(Graybiel, 2000). The direct and indirect pathways are tradition-
ally described in reference to dorsal striatal circuitry, but similar
pathways are thought to exist in in the NAc (Figure 1B) (Sesack
and Grace, 2010). Corticostriatal-limbic circuitry is important for
selecting and amplifying behaviors (Yin and Knowlton, 2006).
FIGURE 1 | Simplified schematic of corticostriatal-limbic circuitry. (A)
Key corticostriatal-limbic connections where gut-brain peptides may act
to influence addictive behaviors. AMG, amygdala; DS, dorsal striatum;
GP, globus pallidus; HIPP, hippocampus; LDTg, laterodorsal tegmental
area; SN, substantia nigra; STN, subthalamic nucleus; VP, ventral
pallidum; VS, ventral striatum; VTA, ventral tegmental area. (B) A
hypothetical schematic of the direct and indirect pathways in the VS.
Glutamatergic projections from the cortex synapse onto MSNs
expressing predominantly dopamine D1 receptors (D1R) or dopamine D2
receptors (D2R). MSNs expressing D1R may project directly to the VP
or the substantia nigra (SN) pars reticulata forming the direct pathway.
Inhibition of GABAergic neurons in the VP or SN can then disinhibit
downstream thalamocortical targets. MSNs expressing dopamine D2
receptors project to the VP which synapses onto glutamatergic neurons
in the STN. Therefore, activation of the indirect pathway results in
reduced glutamatergic projections to the SN pars reticulata. Another
possible indirect pathway involves projections from the VP to
dopaminergic neurons in the VTA. The VTA may inhibit downstream
thalamocortical targets. Green, glutamatergic fibers; red, dopaminergic
fibers; blue, GABAergic fibers; purple, cholinergic fibers.
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Thus, parallel and serial connections within corticostriatal-limbic
circuitry are thought to underlie various phenotypes associated
with the stages of AUD.
AUD can be separated into three stages: (1) binge/intoxication,
(2) preoccupation/anticipation, (3) withdrawal/negative affect
(Koob and Volkow, 2010). The binge/intoxication stage refers to
initial alcohol consumption. Increased sensitivity to the intoxicat-
ing effects often deters consumption, while increased sensitivity
to the rewarding effects of alcohol may promote intake (King
et al., 2011). Alcohol reward seems to be primarily mediated
by the alcohol-induced dopamine response in the NAc. Alcohol
enhances the firing of the VTA, which projects to the NAc, and
this is associated with the perception of alcohol reward (Gessa
et al., 1985; Volkow et al., 2009). Here, we discuss how neu-
rotensin has potential for reducing baseline consumption through
enhancing sensitivity to the intoxicating effects of alcohol and
possibly reducing alcohol reward (Figure 2). In addition, GLP-1
may suppress heavy drinking by reducing the rewarding effects of
alcohol (Figure 3). During the early stages of AUD, positive rein-
forcement likely plays a major role. The transition from social
or impulsive alcohol use to uncontrolled compulsive drinking
is hypothesized to involve increased recruitment and plastic-
ity of corticostriatal-limbic circuitry (Koob and Volkow, 2010).
Initially, the ventral circuitry and prefrontal cortex (PFC) plays a
greater role, then in the later stages of AUD the dorsal striatum is
recruited (Everitt et al., 2008). The dorsal striatum can be divided
into the dorsomedial (DMS, caudate) and dorsolateral (DLS,
putamen) striatum. The DMS has been linked to goal-directed
behavior, while the DLS has been associated with habitual behav-
ior (Yin and Knowlton, 2006). During the development of AUD
there may be a shift of control from the DMS to DLS as drink-
ing becomes more compulsive. Some gut-brain peptides or their
receptors are found in the dorsal striatum, but whether they influ-
ence addictive behaviors through altering dorsal striatal function
is an area that needs to be explored.
The preoccupation/anticipation stage, or the craving stage,
often results in relapse and is perhaps the most challenging
aspect of AUD treatment. Conditioned reinforcement or pair-
ing of stimuli with the effects of alcohol, contributes to crav-
ing for alcohol (Weiss, 2005). Conditioned reinforcers, which
were once neutral stimuli, can increase dopamine on their
own and signal expectation of reward (Saunders and Robinson,
2012). Craving and increased motivation to seek alcohol often
occur after reexposure to alcohol or an alcohol-associated cue,
which may induce relapse or reinstatement. The NAc, as well
as the cortical and limbic sites that project to the NAc, are
key sites for conditioned reinforcement and relapse (Weiss,
2005). Here, we discuss evidence that suggests that ghre-
lin receptor antagonists may effectively reduce alcohol craving
(Figure 4).
The withdrawal/negative affect stage predominates after
numerous cycles of alcohol intoxication and withdrawal.
Tolerance develops to the intoxicating effects of alcohol, but
higher, more frequent doses of alcohol can generate more severe
withdrawal symptoms (Goldstein, 1972). Alcohol consumption
may suppress feelings of dysphoria and anxiety, which can fur-
ther escalate alcohol drinking (Gilman et al., 2008). The amygdala
appears to regulate negative affect related to alcohol withdrawal
(Koob, 2013). Excessive glutamate in the PFC and striatum has
also been linked to withdrawal symptoms (Hinton et al., 2012;
Bauer et al., 2013). Here, we discuss how substance P (Figure 5)
and NPY (Figure 6) are promising targets for reducing especially
stress-mediated relapse.
ANIMAL MODELS FOR AUD
Animal models have been essential to advance AUD research.
Inbred mouse strains, with an essentially homozygous genetic
background at every locus, have been useful to study the under-
lying molecular mechanisms of AUD. C57BL/6J inbred mice are
known to drink the most alcohol whereas DBA/2J inbred mice
drink very little alcohol (Belknap et al., 1993; Moore et al.,
2010). C57BL/6J x DBA/2J recombinant inbred strains have
been used to identify the genetics behind addictive behaviors
(Cunningham, 1995). Another technique for generating animal
models for AUD is selective breeding of high alcohol-preferring
rats or mice. Here we will discuss findings related to gut-brain
peptides in Indiana University alcohol-preferring (P) rats (vs.
alcohol-non-preferring, NP), alcohol-accepting (AA) rats (vs.
alcohol-non-accepting, ANA), high-alcohol-drinking (HAD) rats
(vs. low-alcohol-drinking, LAD) and Warsaw high-preferring
(WHP) rats (vs. Warsaw low-preferring, WLP). Although these
rats have all been bred to have the same phenotype, i.e., high
alcohol consumption, they differ in their genetic background. For
example, P rats are derived from outbred Wistar rats, whereas the
HAD line is derived from N/Nih rats (Li et al., 1979, 1993). P
and NP rats are commonly used since they model many aspects of
AUD, such as binge- and relapse-like drinking (Bell et al., 2006).
P rats exhibit anxiety-like behavior and are sensitive to the anxi-
olytic effects of alcohol (Stewart et al., 1993). Mice have also been
selectively bred for their sensitivity to alcohol-induced loss of
righting reflex or the hypnotic effect of alcohol. These long-sleep
(LS) and short-sleep (SS) mice and recombinant inbred LL × SS
lines have been used to examine the genetics behind differences
in sensitivity to the intoxicating effects of alcohol (Bennett et al.,
2006). Lastly, specific genetic effects on alcohol-related behaviors
can be studied by knockout, knockin, and transgenic mice.
There are numerous different behavioral paradigms that
are used to model AUD-like behaviors in animals. Baseline
alcohol consumption resembling the binge/intoxication stage
of AUD is often measured in animals by two-bottle choice
drinking (continuous, limited or intermittent access), operant
self-administration or binge-like drinking-in-the-dark (Samson
et al., 1988; Belknap et al., 1993; Rhodes et al., 2005). Limited
and intermittent access paradigms are especially valuable since
they appear to better model escalated alcohol consumption seen
in humans, and the transition to other stages of AUD, such
as withdrawal (Hwa et al., 2011). To investigate sensitivity to
alcohol-induced sedation and ataxia in animals, performance on
the rotarod and alcohol-mediated loss of righting reflex is often
examined (Crabbe et al., 1981; Dar, 1996). Alcohol-mediated
conditioned place preference (CPP) and brain stimulation reward
thresholds are typically used to evaluate alcohol reward sensi-
tivity (Kornetsky, 1985; Cunningham et al., 2006). Anticipation
for, or motivation to, consume alcohol in animals (similar to
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the preoccupation/anticipation stage) is often measured by pro-
gressive ratio operant responding where the breakpoint, or the
maximum number of responses for a single reward, is determined
(Stafford et al., 1998). Alcohol preoccupation/anticipation may
lead to relapse which can be studied in animals by assessing drug-
and cue-induced reinstatement (Sanchis-Segura and Spanagel,
2006). Furthermore, negative affect related to alcohol withdrawal
can be examined in animals by conditioned place aversion and
anxiety measures (e.g., elevated plus maze, time in the center
of the open field) (Valdez et al., 2002; Prut and Belzung, 2003;
Cunningham et al., 2006). The severity of alcohol withdrawal
is often quantified by handling-induced convulsions in rodents
(Metten and Crabbe, 2005). Stress and anxiety outside of alcohol
withdrawal may also promote relapse which can be assessed in
rodents by quantifying alcohol reinstatement after a pharmaco-
logical stressor (yohimbine), for example (Marinelli et al., 2007).
In this review, we will discuss how several gut-brain peptides may
influence AUD-related behaviors as demonstrated in animal and
human studies.
NEUROTENSIN
Neurotensin (NT) is a 13-amino-acid (a.a.) peptide originally
isolated from the bovine hypothalamus (Carraway and Leeman,
1973). NT is expressed in many tissues both centrally and periph-
erally. In the CNS, NT is widely expressed at high levels in the
amygdala, hypothalamus, SN and VTA, and at lower levels in
areas such as the hippocampus, cortex and striatum (Manberg
et al., 1982; Stolakis et al., 2010; Boules et al., 2013). Thus, NT
is found within corticostriatal-limbic circuitry where it acts as
a neurotransmitter and neuromodulator (Binder et al., 2001a;
Ferraro et al., 2008; Petkova-Kirova et al., 2008a,b). Centrally, NT
has a wide range of actions. NT plays a role in opioid-independent
antinociception (Kleczkowska and Lipkowski, 2013), hypother-
mia (Bissette et al., 1976), blood pressure (Sumners et al., 1982),
anterior pituitary hormone secretion (Rostene and Alexander,
1997; Stolakis et al., 2010), food intake (Cooke et al., 2009), and
sleep (Fitzpatrick et al., 2012). NT also possesses antipsychotic-
like effects, which are largely attributed to NT-mediated regula-
tion of dopaminergic signaling (Binder et al., 2001b; Kinkead and
Nemeroff, 2004, 2006; Vadnie et al., 2014). The neuromodulatory
role of NT on dopamine signaling also makes NT an attractive
target for substance abuse research.
NT exerts its effects by acting on three receptor subtypes
(NTS1, NTS2, and NTS3; Vincent et al., 1999). NTS1 and NTS2
are G-protein-coupled receptors through which NT primarily
exerts its effects. NTS1 has the highest affinity for NT and is
broadly expressed in the CNS (Pelaprat, 2006). NTS1 is found
in areas such as the SN, VTA, NAc, hypothalamus, amygdala,
PFC, hippocampus, and dorsal root ganglia of the spinal cord
(Alexander and Leeman, 1998; Fassio et al., 2000). NTS2 is local-
ized to many of the same brain regions as NTS1 (Mazella et al.,
1996; Walker et al., 1998; Sarret et al., 2003). However, there are
FIGURE 2 | Regulation of alcohol consumption by neurotensin. (A)
Neurotensin (NT) has opposing presynaptic and postsynaptic effects on
dopaminergic signaling in the nucleus accumbens (NAc). Presynaptically,
NT may increase dopamine (DA) release through neurotensin receptor
type 1 (NTS1)-, or possibly even neurotensin receptor type 2
(NTS2)-mediated inhibition of dopamine D2 receptors (D2R) on ventral
tegmental area (VTA) dopaminergic (DAergic) terminals. Postsynaptically,
NTS1 or even NTS2 dimerizes with D2R and attenuates D2R signaling.
Functional studies suggest that the effect of NT on inhibiting
postsynaptic D2R signaling may predominate in the nucleus accumbens
(NAc). (B) Alcohol increases dopamine release in the NAc. Alcohol may
excite VTA dopaminergic neurons by inhibiting GABAergic interneurons in
the VTA, which results in reduced activation of GABA receptors (GABAR)
on VTA dopaminergic neurons. Increased VTA-mediated dopamine in the
NAc may promote alcohol consumption and mediate alcohol reward. NT
receptor agonists may reduce alcohol consumption by acting on
postsynaptic NT receptors which may inhibit alcohol-mediated dopamine
signaling in the NAc.
Frontiers in Neuroscience | Neuropharmacology September 2014 | Volume 8 | Article 288 | 4
Vadnie et al. Gut-brain peptides in AUD
especially high levels of NTS2 in areas associated with pain, where
NT agonists have been shown to regulate pain through NTS2
independent of NTS1 (Dubuc et al., 1994; Boules et al., 2010).
NEUROTENSIN AND CORTICOSTRIATAL-LIMBIC CIRCUITRY
NT and NTS1 are highly expressed in the mesocorticolimbic
dopamine pathways (Binder et al., 2001a) where NT regulates
dopamine transmission mainly through NTS1. NT-mediated
activation of NTS1 is known to inhibit dopamine D2 recep-
tor (D2R) function through a direct NTS1/D2 receptor–receptor
interaction which results in a reduced affinity of D2R for
dopamine (Figure 2A; Koschatzky et al., 2011). NT may pro-
mote the internalization of D2R and may reduce D2R signaling
(Jomphe et al., 2006; Thibault et al., 2011; Borroto-Escuela et al.,
2013). Conversely, NT or NT analogs increased tyrosine hydrox-
ylase gene expression and dopamine release, which may be medi-
ated by NTS1 on dopaminergic neurons (Kalivas and Duffy, 1990;
Burgevin et al., 1992; Wang et al., 2004; Jomphe et al., 2006).
The opposing presynaptic and postsynaptic effects of NTS1 on
striatal dopaminergic signaling complicate our understanding of
NT’s role in the modulation of striatal-mediated addictive behav-
iors. When NT is injected into the NAc, it reduces the response
to psychostimulants (Ervin et al., 1981; Robledo et al., 1993).
Conversely, higher concentrations of NT in the NAc increase
dopamine release, which may be mediated by NTS1 on presynap-
tic dopaminergic terminals, and would be predicted to enhance
the effects of psychostimulants (Figure 2A) (Reyneke et al., 1990;
Chapman et al., 1992). Immunohistochemistry and behavioral
studies suggest that in the dorsal striatum there is a higher den-
sity of NTS1 on dopaminergic terminals relative to postsynaptic
MSNs (Ervin et al., 1981; Li et al., 1995; Boudin et al., 1996;
Peltonen et al., 2012). Systemic administration data argue that the
postsynaptic antagonistic effects of NTS1 on D2R function may
predominate since brain-penetrating NT analogs given systemi-
cally reduce the pharmacological effects of psychostimulants and
do not appear to be rewarding (Binder et al., 2001b; Fantegrossi
et al., 2005). Thus, NTS1 activationmaymodulate alcohol-related
behaviors by inhibiting D2R signaling in striatopallidal MSNs
in the NAc (Figure 2B), but not in the dorsal striatum where
stimulation of NTS1 may promote dopamine signaling.
Recently, an in vitro study showed that in the presence of NT
and NTS2, D2R exhibits a reduced affinity for dopamine simi-
lar to NTS1 (Koschatzky and Gmeiner, 2012). In addition, the
NTS2 selective agonist NT79 was shown to block amphetamine-
mediated hyperactivity like NTS1 agonists (Boules et al., 2010).
These studies suggest that NTS2 may also inhibit dopamine sig-
naling (Figure 2A). Beyond these studies, the role of NTS2 in
regulating addictive behaviors through dopamine signaling has
been relatively unexplored.
NT may also regulate glutamate transmission in
corticostriatal-limbic circuitry. The NT analog NT69L inhibited
alcohol-mediated glutamate release in the striatum (Li et al.,
2011). Alcohol has a biphasic effect on striatal extracellular
glutamate levels with low doses increasing and high doses
decreasing extracellular glutamate (Moghaddam and Bolinao,
1994; Chen et al., 2010). This suggests that NTS1 or NTS2
activation may inhibit the acute effects of low doses of alcohol
in the striatum. However, the mechanism behind this effect
is unclear since other studies have suggested that NT alone
promotes glutamatergic signaling (Ferraro et al., 2011). NTS1 has
been shown to functionally interact with glutamatergic NMDA
receptors, potentiating NMDA receptor function (Ferraro et al.,
2012). Alcohol is a known to inhibit NMDA function (Lovinger
et al., 1989). Thus, it is possible that NTS1 agonists may also
inhibit some effects of alcohol through a synergistic interaction
with NMDA receptors.
NEUROTENSIN AND ALCOHOL IN HUMAN STUDIES
Two human studies have found links between NTR1 single-
nucleotide polymorphism (SNPs) and AUD in humans (Agrawal
et al., 2011; Ma et al., 2013). Three NTR1 SNPs (rs3787535,
rs6089930, and rs3915568) were found to be significantly asso-
ciated with consumption factor scores in 827 young adult twin
women from the Missouri Adolescent Female Twin Registry
(Agrawal et al., 2011). However, these findings were not replicated
in a separate cohort. Another study observed significant associ-
ations between two NTR1 SNPs (rs6011914 and rs2427422) and
alcohol dependence in Han Chinese males (Ma et al., 2013). Thus,
certain NTR1 genotypes in humans may increase susceptibility
for AUD.
Alcohol has also been shown to affect plasma NT levels
in humans. Oral consumption of alcohol (1 g/kg) by healthy
men transiently increased plasma NT levels (Szulc et al., 1991).
Therefore, NT may be involved in the physiological effects of
alcohol in humans.
NEUROTENSIN AND ALCOHOL IN ANIMAL MODELS
NT appears to contribute to the neurochemical and behavioral
effects of alcohol in animal models. Administration of NT into
the brain (since NT does not readily cross the BBB and is easily
degraded) induces hypothermia (Bissette et al., 1976), hypolo-
comotion (Nemeroff et al., 1977), and striatal dopamine release
(Kalivas and Duffy, 1990) similar to alcohol. NT also enhances
alcohol-induced loss of righting reflex and hypothermia (Frye
et al., 1981; Luttinger et al., 1983). Furthermore, cross-tolerance
develops between alcohol and NT to their locomotor inhibitory
and hypothermic effects, indicating that NT affects sensitivity
to alcohol-induced intoxication (Erwin et al., 1995). LS and SS
mice, which differ in their sensitivity to alcohol-induced seda-
tion, were found to exhibit differences in brain NT concentration,
brain NT receptor levels, and in behavioral responses to NT
(Erwin and Jones, 1989; Erwin et al., 1990). Thus, differences
in NT signaling in the brain may partially explain why LS mice
are more sensitive to alcohol-induced sedation. In support of
this, a couple of studies have identified quantitative trait loci
(QTL) linked to both NTS1 levels in the striatum and sensi-
tivity to alcohol hypnosis (Erwin and Jones, 1993; Erwin et al.,
2001). NT has also been linked to alcohol consumption since P
rats, which were selectively bred to consume high amounts of
alcohol, were reported to have reduced NT levels in the frontal
cortex relative to NP rats (Ehlers et al., 1999). Together, these
findings suggest enhanced NT signaling increases sensitivity to
the intoxicating effects of alcohol, which may reduce alcohol
consumption.
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Conversely, alcohol regulates NT signaling. Chronic alcohol
exposure was reported to increase NT in the dorsal striatum in
rats (Wachi et al., 1996). In mice, both chronic and acute alcohol
decreased NTS1 and NTS2 in the NAc and midbrain (Campbell
and Gene Erwin, 1993). These findings suggest that alcohol may
increase NT levels and decrease NT receptor expression, which
may reduce alcohol sensitivity and promote alcohol consump-
tion. Alcohol-mediated reduction of NT receptors may explain
why cross-tolerance exists between NT and alcohol. It also sug-
gests that NT signaling contributes to tolerance to the intoxicating
effects of alcohol.
Neurotensin receptor type 1 and alcohol
Since NTS1 inhibits D2R function and potentially regulates gluta-
mate signaling, NTS1 is a promising therapeutic target for AUD.
We have shown that NTS1 KO mice are less sensitive to the ataxic
effect of alcohol and consume more alcohol relative to wildtype
mice in a two-bottle choice drinking study (Table 1; Lee et al.,
2010). In this same study, we used a BBB permeable synthetic
NT analog, NT69L, to reduce two-bottle choice alcohol consump-
tion while enhancing sensitivity to alcohol-mediated ataxia in
mice. NT69L acts as an agonist with relatively equal affinity for
NTS1 and NTS2 (Boules et al., 2006). However, it was observed
that NT69L did not decrease alcohol consumption or enhance
alcohol-induced ataxia in NTS1 KO mice (Lee et al., 2010). Our
findings suggested that NTS1 activation increases sensitivity to
alcohol intoxication while decreasing voluntary baseline alcohol
consumption.
NTS1 has also been implicated in sleep and psychiatric
disorders which often co-occur with AUD and can increase
the proclivity for relapse. NTS1 KO mice spent less time in rapid
eye movement sleep (REM), but more time in non-REM sleep
(Fitzpatrick et al., 2012).The same study found thatNTS1KOmice
exhibited anxiety- and depression-like behaviors. Furthermore,
there is a substantial amount of work demonstrating the antipsy-
chotic effects of NTS1 agonists in rodents (Kinkead andNemeroff,
2006; Boules et al., 2013). These data suggest that NTS1 agonists
may also be useful in treating alcohol addiction with comor-
bid psychiatric or sleep disorders. However, additional research is
needed to elucidate theprecise roleofNTS1 inalcoholdependence.
Neurotensin receptor type 2 and alcohol
NTS2 also seems to play a role in alcohol sensitivity and con-
sumption. In LS and SS recombinant inbred strains, a negative
correlation betweenNTS2 density in the frontal cortex and volun-
tary alcohol consumption was reported (Gehle and Erwin, 1998).
More recently, we found that NTS2 KO mice were less sensi-
tive to alcohol-induced sedation and consumed more alcohol in
comparison to wildtype mice in a two-bottle choice paradigm
(Table 1; Lee et al., 2011). However, NT69L attenuated baseline
alcohol consumption and preference in wildtype as well as in
NTS2 KO mice (Lee et al., 2011). This confirmed previous find-
ings that NTS1 seems to be responsible for the effect of NT69L
on reducing alcohol consumption. In future studies, the use of
NTS2-selective agonists will help to elucidate the role of NTS2 in
alcohol consumption. Although these studies suggest that NTS2
enhances sensitivity to higher hypnotic doses of alcohol while
NTS1 increases sensitivity to lower ataxic doses of alcohol, and
by these mechanisms both receptors may suppress alcohol con-
sumption (Lee et al., 2011). Further research is necessary to
determine if NTS2 may regulate alcohol consumption by other
mechanisms besides simply increasing sensitivity to the sedative
effect of alcohol.
SUMMARY
Recent animal behavioral data suggests that NTS1 agonists may
be useful for suppressing baseline drinking or binge drink-
ing (Lee et al., 2010). NT agonists could be a novel treatment
for reducing alcohol consumption by enhancing the intoxicat-
ing effects and by possibly reducing the rewarding/reinforcing
effects of alcohol. Interestingly, NT is thought to increase stri-
atopallidal GABA transmission in the NAc, which may explain
some of its effects (Li et al., 1995). Activation of striatopallidal
neurons may reduce drug administration and decrease locomo-
tor activity (Lobo and Nestler, 2011; Farrell et al., 2013). NT
agonists may also reduce alcohol consumption by inhibiting
alcohol-mediated glutamate signaling in the striatum or cortex
(Li et al., 2011). Given the dopaminergic and glutamatergic neu-
romodulatory roles of NT in the striatum, further research is
needed to uncover if NT agonists also affect alcohol reward, binge
drinking, conditioned reinforcement and reinstatement in animal
models.
GLP-1
GLP-1 is a 30-a.a. peptide and a member of a class of molecules
referred to as incretins, which facilitate food intake-stimulation
of insulin release (Perfetti andMerkel, 2000). Clinical use of GLP-
1 for diabetes was limited by its rapid degradation by dipeptidyl
peptidase-4 (DPP-4) and other peptidases (Hansen et al., 1999).
Then a major breakthrough occurred with the discovery of a pep-
tide similar in structure and function to GLP-1, exendin-4 (Ex4),
that is resistant to degradation by DPP-4 (Thorens et al., 1993;
Young et al., 1999). Ex4 and another GLP-1 analog, liraglutide,
are now FDA-approved for the treatment of type II diabetes.
Besides glycemic control, there is increasing interest in GLP-1
for the treatment of obesity and addiction (Reddy et al., 2013;
Skibicka, 2013). Central and peripheral administration of GLP-
1 reduces food consumption, an effect that was thought to be
primarily mediated by the hypothalamus and brainstem nuclei
(Turton et al., 1996; Naslund et al., 1999; Schick et al., 2003; Hayes
et al., 2009). GLP-1 is produced in the nucleus of the solitary tract
in the brainstem, which projects to numerous areas of the CNS
expressing the GLP-1 receptor (GLP-1R), such as the hypothala-
mus (Dickson et al., 2012). Since GLP-1 is rapidly degraded by
DPP-4 and both peripheral and central GLP-1 reduces food con-
sumption, it has been proposed that there may be a signaling link
between peripheral GLP-1R activation and central GLP-1 release
from the nucleus of the solitary tract (Trapp and Hisadome,
2011). One possible mechanism would be GLP-1R-mediated acti-
vation of the vagus nerve which projects to the nucleus of the
solitary tract.
GLP-1R is widely expressed in brain, not just in the hypotha-
lamus and brainstem. GLP-1R is detected in areas such as
the hippocampus, amygdala, NAc, VTA, SN, and pituitary
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FIGURE 3 | Possible mechanisms by which GLP-1 may reduce alcohol
consumption. (A) Glucagon-like peptide 1 (GLP-1), by acting on the GLP-1
receptor (GLP-1R) on presynaptic glutamatergic (GLUergic) terminals in the
ventral tegmental area (VTA), may increase glutamate (GLU) release.
Increased glutamate release in the VTA may enhance the activity of VTA
dopaminergic (DAergic) neurons through glutamatergic AMPA receptors
(AMPARs) or kainate receptors (KARs). Increased activity of VTA
dopaminergic neurons may then promote dopamine release in postsynaptic
targets such as the amygdala (AMG). Increased dopamine D2 receptor (D2R)
signaling in the amygdala has been linked with decreased food intake and
therefore may mechanistically explain how GLP-1 decreases alcohol
consumption. (B) GLP-1 through GLP-1R on presynaptic glutamatergic
terminals may increase glutamate release in the nucleus accumbens (NAc).
Increased NAc glutamate may activate AMPARs or KARs which may reduce
alcohol consumption by enhancing the activity of striatopallidal medium spiny
neurons (MSNs).
(Merchenthaler et al., 1999). Thus, the expression pattern of
GLP-1R suggests GLP-1 has additional roles in the CNS. Recent
work has implicated GLP-1 in learning, stress, and reward
(During et al., 2003; Kinzig et al., 2003; Alhadeff et al., 2012).
Therefore, central GLP-1 signaling could be a relevant therapeutic
target for AUD.
GLP-1 AND CORTICOSTRIATAL-LIMBIC CIRCUITRY
GLP-1 may decrease the rewarding effect of food and drugs
of abuse by acting on the mesolimbic pathway (Dossat et al.,
2011; Alhadeff et al., 2012; Dickson et al., 2012). Peripheral
administration of the GLP-1 analog, Ex4, decreased food reward
and food seeking in rats (Dickson et al., 2012). Microinjection
of Ex4 into the VTA or into the NAc reduced motivation for
food, as determined by progressive ratio responding for sucrose,
and food consumption (Alhadeff et al., 2012; Dickson et al.,
2012). These studies suggest that GLP-1R in the NAc and VTA
may play a role in natural reward and reinforcement. Ex4 also
reduced amphetamine- and cocaine-induced locomotion, reward
and NAc dopamine release (Erreger et al., 2012; Graham et al.,
2012; Egecioglu et al., 2013). However, Ex4 had no effect on
accumbal dopamine levels alone (Egecioglu et al., 2013). These
studies indicate that GLP-1R-mediated attenuation of rewardmay
be linked to an inhibition of drug-induced dopamine release in
the NAc.
In the mesolimbic system, neurons (such as those in the
nucleus of the solitary tract) projecting to the VTA and NAc are
the most likely source of endogenous GLP-1. However, the mech-
anism by which GLP-1 in the mesolimbic pathway reduces food
or drug intake is not clear (Alhadeff et al., 2012). A recent study
suggests that GLP-1R activation surprisingly increased dopamin-
ergic neuron activity in the VTA (Mietlicki-Baase et al., 2013).
Ex4 increased VTA tyrosine hydroxylase expression which sug-
gests that GLP-1R activation may increase dopamine synthesis
and release. In this same study, the anorexic effect of microin-
jection of Ex4 into the VTA was reduced by an AMPA/kainate
antagonist and Ex4 increased AMPA/kainate receptor-mediated
sEPSC frequency in VTA dopaminergic neurons. Thus, these
findings suggest that presynaptic GLP-1R activation on gluta-
matergic terminals in the VTA may increase VTA dopaminergic
neuron firing through AMPA/kainate neurotransmission. Since
increased VTA firing would be expected to increase food intake
and reward sensitivity, it is controversial. One possibility, as sug-
gested by a recent study, is that GLP-1R activation in the VTA
may preferentially increase dopamine in the amygdala rather than
in the NAc (Anderberg et al., 2014). Amygdala dopamine D2R
activation was observed to decrease food intake and i.c.v. admin-
istration of Ex4 increased dopamine turnover in the amygdala
(Anderberg et al., 2014). The anorexigenic effect of Ex4 appeared
to be at least partially mediated by D2R activation in the amygdala
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since a D2R antagonist attenuated the effect of Ex4 on suppress-
ing food intake. Additional studies are required to clarify whether
GLP-1R activation in the VTA increases amygdala dopamine lev-
els as we propose in Figure 3A. Regardless, this does not explain
how microinjection of Ex4 in the NAc reduces food intake.
To address the role of GLP-1 in the NAc, the same group
investigated how Ex4 affects the activity of NAc MSNs (Mietlicki-
Baase et al., 2014). Interestingly, Mietlicki-Baase et al. (2014)
found, similar to the VTA, that Ex4 increases the activity of NAc
MSNs by enhancing AMPA/kainate receptor-mediated mEPSCs
and this effect appeared to be independent of postsynaptic GLP-
1Rs on MSNs. Secondly, Ex4 in the NAc reduced food intake and
this effect was reduced by an AMPA/kainate receptor antagonist.
Finally, Ex4 alone did not enhance NAc dopamine as measured
by ex vivo fast-scan cyclic voltammetry. Together, this suggests
that Ex4 acts GLP-1Rs on presynaptic glutamatergic terminals
to excite MSNs and reduce food intake. As shown in Figure 3B,
since it is hypothesized that activation of striatopallidal neurons
reduces administration of drugs of abuse, it is possible that GLP-1
may predominantly excite MSNs in the indirect pathway by this
glutamatergic mechanism (Lobo and Nestler, 2011). Thus, GLP-
1-mediated activation of MSNs may reduce the administration of
rewarding substances, such as alcohol, by increasing the inhibi-
tion of downstream targets of the NAc.
GLP-1 AND ALCOHOL IN HUMANS
GLP-1 analogs have been deemed clinically safe, but there is
no clear evidence that they reduce alcohol intake in humans.
However, some studies have shown that bariatric surgery reduces
alcohol intake in humans while increasing circulating GLP-1 in
response to food (Woodard et al., 2011; Davis et al., 2012; Yousseif
et al., 2014). Increased circulating GLP-1 is thought to play a key
role in the efficacy of bariatric surgery. These studies imply that
GLP-1 analogs may be beneficial in reducing alcohol intake in
humans.
GLP-1 AND ALCOHOL IN ANIMAL MODELS
GLP-1R activation has been shown to reduce alcohol con-
sumption, alcohol reward, and motivated alcohol seeking. GLP-
1R activation inhibited alcohol reward as demonstrated by
reduced alcohol-induced locomotor activity, CPP and accumbal
dopamine release with peripheral Ex4 administration in outbred
mice (Egecioglu et al., 2012). Ex4 also reduced alcohol intake
in an intermittent alcohol access paradigm and the break point
for progressive ratio operant self-administration of alcohol in
Wistar rats (Egecioglu et al., 2012). This implies that GLP-1R acti-
vation suppresses motivation to obtain alcohol. Corroborating
these findings, another study reported that peripheral adminis-
tration of GLP-1 and/or Ex4 reduced alcohol consumption in
an intermittent access paradigm in Wistar rats and alcohol CPP
in outbred mice (Shirazi et al., 2013). Moreover, a peripherally
administered GLP-1R antagonist increased alcohol consumption
while GLP-1R activation in the VTA was sufficient to reduce
alcohol consumption in rats, indicating that the effect may be
mediated by GLP-1R in the VTA (Shirazi et al., 2013). The study
also indicated that within a certain dosage range, GLP-1R agonists
may reduce alcohol consumption without affecting preference for
natural rewards, since a lower dose of Ex4 that reduced alcohol
intake did not alter water or food consumption (Shirazi et al.,
2013).
Ex4 also appears to more effectively reduce alcohol con-
sumption in rats consuming higher amounts of alcohol, sug-
gesting that GLP-1 analogs may treat heavy drinking or binge
drinking (Shirazi et al., 2013). Chronic heavy drinking may
lead to brain neurodegeneration associated with memory and
motor deficits. Approximately 10% of dementia cases have been
linked to alcohol-related dementia (Gupta and Warner, 2008).
Interestingly, Ex4 promoted adult neurogenesis in vitro and
in vivo (Bertilsson et al., 2008), indicating that GLP-1R ago-
nists could slow or even reverse neurodegenerative processes
(Perry et al., 2002). Ex4 also improved memory performance
and reduced depression-like behavior (Isacson et al., 2011). The
potential cognitive and neurogenesis enhancing effects of GLP-
analogs may be an additional benefit for using GLP-1R agonists
as a treatment for AUD.
SUMMARY
GLP-1 analogs, such as Ex4, may be effective therapeutics for
AUD. Preclinical data suggest that Ex4 may reduce alcohol reward
and motivation. Furthermore, Ex4 may be especially useful for
suppressing heavy drinking and alcohol-mediated neurodegener-
ation. However, more work is necessary to uncover the mech-
anism behind the anti-drinking effect of GLP-1 analogs. The
majority of studies have focused on the effect of GLP-1R acti-
vation on the mesolimbic pathway. Recent findings indicate that
GLP-1R activation may reduce the administration of rewarding
substances by promoting glutamatergic signaling in the VTA and
NAc, but further studies are needed to confirm this theory and
clarify whether mesolimbic dopaminergic signaling is important.
GLP-1R is also found in the SN and it is possible that the nigros-
triatal pathway could play an important role in the suppressive
action on Ex4 on alcohol consumption (Merchenthaler et al.,
1999).
GHRELIN
Ghrelin is a 28-a.a. peptide that is mainly synthesized and
released by mucosal cells in the stomach. Ghrelin was originally
named after its ability to act on the growth hormone secre-
tagogue receptor 1a (GHS-R1a) in the pituitary to stimulate
growth hormone release (Kojima et al., 1999). Acylation of ghre-
lin, which is catalyzed by the enzyme ghrelin O-acyltransferase
(GOAT), is required for ghrelin to bind to GHS-R1a (Yang et al.,
2008).
Ghrelin is well known for its orexigenic effects. Ghrelin level
in the blood is higher after fasting and lower after food intake
(Cummings et al., 2001). Both peripheral and central administra-
tion of ghrelin stimulates food intake and increases body weight
(Tschöp et al., 2000; Wren et al., 2000). GHS-R1a blockade has
the opposite effect of reducing food consumption (Salome et al.,
2009). Ghrelin primarily promotes food consumption by acting
indirectly and directly on the hypothalamus. Ghrelin indirectly
activates the hypothalamus through the vagus nerve which acts
on the nucleus of the solitary tract in the brainstem which then
projects to the arcuate nucleus of the hypothalamus (Date et al.,
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FIGURE 4 | Ghrelin signaling and alcohol consumption. (A) One
mechanism by which ghrelin may increase ventral tegmental area (VTA)
dopaminergic neuron activity and nucleus accumbens (NAc) dopamine
(DA) levels involves ghrelin-mediated activation of laterodorsal tegmental
area (LDTg) cholinergic neurons. Ghrelin through growth hormone
secretagogue receptor 1a (GHS-R1a) may activate LDTg cholinergic
neurons and subsequently increase acetylcholine (ACh) levels in the VTA.
Activation of nicotinic acetylcholine receptors (nAChR) on VTA
dopaminergic neurons can increase neuronal activity and promote
dopamine release in postsynaptic regions. Increased dopamine signaling
may explain how ghrelin can promote alcohol consumption. (B) There is
also evidence that ghrelin may activate VTA dopaminergic neurons by
promoting presynaptic glutamate (GLU) release in the VTA. Ghrelin
through GHS-R1a on glutamatergic terminals in the VTA may enhance
glutamate release. Subsequent activation of NMDA receptors (NMDAR)
could then increase VTA dopaminergic activity. (C) Finally, ghrelin through
GHS-R1a may activate glutamatergic ventral hippocampal (vHIPP) neurons,
which may result in increased glutamate release in the NAc. Increased
glutamate in the NAc may increase dopamine release by activating
glutamate receptors on presynaptic dopaminergic terminals. Increased
activation of dopamine D1 or D2 receptors (D1R/D2R) on medium spiny
neurons (MSNs) in the NAc may then promote alcohol consumption.
2002). Ghrelin may also directly act on homeostatic feeding areas
in the brain since ghrelin crosses the BBB (Banks et al., 2002);
it can also reach the hypothalamus through areas which are not
fully protected by the BBB (Merchenthaler, 1991). In support of
this, central administration of ghrelin reduces feeding and a study
has shown that peripheral ghrelin still increases feeding after vagal
deafferentation (Tschöp et al., 2000; Arnold et al., 2006).
Although most circulating ghrelin comes from the stomach,
ghrelin mRNA is widely detected in the brain; however, it is
debatable whether ghrelin is released at physiologically meaning-
ful levels in the CNS (Gnanapavan et al., 2002; Furness et al.,
2011). Nevertheless, since peripheral ghrelin can cross the BBB
(Banks et al., 2002), and GHS-R1a possesses constitutive (or
ligand-independent) activity (Holst et al., 2003), GHS-R1a likely
exerts its effect on brain function even with inadequate produc-
tion of central ghrelin. In the brain, GHS-R1a is also expressed in
areas outside the hypothalamus, such as in the hippocampus, SN,
VTA, cortex and amygdala (Guan et al., 1997; Zigman et al., 2006;
Alvarez-Crespo et al., 2012). Recently ghrelin was shown to affect
reward (Skibicka and Dickson, 2011), locomotion (Jerlhag et al.,
2006), mood (Kanoski et al., 2013), andmemory (Alvarez-Crespo
et al., 2012).
GHRELIN AND CORTICOSTRIATAL-LIMBIC CIRCUITRY
Ghrelin and GHS-R1a have been shown to affect mesocor-
ticolimbic dopaminergic signaling. When administered intra-
venously to humans, functional magnetic resonance imaging
(fMRI) revealed ghrelin increased the activity of the VTA and
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the regions it projects to (amygdala, striatum, hippocampus,
cortex) when viewing pictures of food (Malik et al., 2008).
GHS-R1a is expressed presynaptically and postsynaptically in
the VTA (Abizaid et al., 2006) as well as on cholinergic neu-
rons in the laterodorsal tegmental area (LDTg) (Dickson et al.,
2010). Cholinergic neurons in the LDTg project to and excite
VTA dopaminergic neurons (Woolf, 1991). In mice, microinjec-
tion of ghrelin into the VTA or LDTg increased dopamine in
the NAc (Jerlhag et al., 2007). This suggests that ghrelin may
act locally on VTA neurons or increase the activity of mesolim-
bic dopaminergic neurons through indirect mechanisms, such
as enhancing cholinergic input from the LDTg (Figure 4A). In
fact, a nicotinic acetylcholine receptor antagonist was shown to
block the effect of ghrelin in the LDTg on dopamine release
in the NAc (Jerlhag et al., 2008). This suggests that nicotinic
acetylcholine receptors can modulate the effects of ghrelin on
mesolimbic dopaminergic signaling and reward. It is possible that
peripheral ghrelin regulates mesolimbic circuitry since peripher-
ally administered ghrelin increased NAc dopamine whereas GHS-
R1a antagonist administration had the opposite effect (Jerlhag,
2008; Jerlhag et al., 2010). Ghrelin did not increase the activ-
ity of VTA dopaminergic neurons in mice lacking GHS-R1a,
suggesting that GHS-R1a-mediated signaling plays an essential
role in regulating dopaminergic neuron activity (Abizaid et al.,
2006). Ghrelin-mediated excitation of VTA dopaminergic neu-
rons may be partially attributed to its effects on synaptic plas-
ticity. Ghrelin administration increased excitatory and decreased
inhibitory synapses onto VTA dopaminergic neurons in mice
(Abizaid et al., 2006). Chronic ghrelin administration altered the
expression of dopaminergic and nicotinic acetylcholine receptors
in the mesolimbic reward circuitry (Skibicka et al., 2012). These
results suggest that changes in ghrelin signaling, such as those
mediated by alcohol, could lead to long-lasting adaptations in the
synaptic plasticity of the reward system.
The actions of ghrelin on mesoaccumbal dopamine appear
to mediate its effects on reward sensitivity. Microinjection of
ghrelin into the VTA and NAc increased feeding in rodents
(Naleid et al., 2005; Abizaid et al., 2006), while lesioning the VTA
blocked ghrelin-induced increases in palatable food consump-
tion (Egecioglu et al., 2010). Ghrelin-mediated increase in natural
reward consumption is dependent on GHS-R1a, since antago-
nism or genetic deletion of GHS-R1a in rodents reduced palatable
food consumption, but not standard chow intake (Egecioglu
et al., 2010). Furthermore, palatable food-mediated CPP was
increased by ghrelin, but blocked by a GHS-R1a antagonist or
genetic deletion of GHS-R1a or ghrelin (Egecioglu et al., 2010;
Perello et al., 2010; Disse et al., 2011). Ghrelin-mediated increase
in NAc dopamine signaling has been shown to play a crucial role
in reward sensitivity since dopamine D1R and D2R antagonists in
the NAc attenuate the ability of VTA ghrelin to increase operant
responding for sucrose (Skibicka et al., 2013). These studies indi-
cate that ghrelin increases reward sensitivity, which is most likely
through its effects on VTA dopaminergic neurons. The effect of
ghrelin on dopaminergic VTA neuronal activity appears to be
modulated by glutamatergic signaling. A NMDA receptor antago-
nist blocked the effects of VTA ghrelin on dopamine release in the
NAc and on locomotor stimulation (Jerlhag et al., 2011a). This
suggests that glutamatergic projections to the VTA are modulated
by the actions of ghrelin (Figure 4B).
Microinjection of ghrelin into the ventral, but not the dor-
sal hippocampus has been shown to increase chow intake in
Sprague–Dawley rats (Kanoski et al., 2013). Ventral hippocam-
pus ghrelin also increased the motivation for natural reward
as determined by an increased breakpoint under a progressive
ratio schedule for sucrose. Furthermore, ghrelin in the ven-
tral hippocampus increased cue-induced feeding. As shown in
Figure 4C, these effects may bemediated by increased glutamater-
gic signaling from the ventral hippocampus to the NAc since
microinjection of ghrelin into the ventral hippocampus increased
phosphorylated tyrosine hydroxylase in the NAc, suggesting
increased dopamine release (Kanoski et al., 2013). The ventral
hippocampus has strong glutamatergic projections to the NAc
and may directly or indirectly affect the local release of dopamine
in the NAc from presynaptic VTA terminals (Groenewegen et al.,
1996; McDonald, 1998). Inactivation of the ventral hippocam-
pus attenuated cue and cocaine-induced reinstatement (Rogers
and See, 2007). Other studies have shown that drug cues acti-
vate the hippocampus (Topple et al., 1998; Kufahl et al., 2009).
It is possible that the ventral hippocampus is essential in retrieval
of alcohol-cue associations. Therefore, ghrelin in the ventral hip-
pocampus may increase the recall of cues associated with alcohol,
which could promote relapse. Microinjection of ghrelin into
the amygdala also increased chow intake (Alvarez-Crespo et al.,
2012). The amygdala plays a key role in assigning emotional and
motivational value to contextual cues. Therefore, ghrelin in the
hippocampus or amygdala may regulate alcohol reinstatement.
GHRELIN AND ALCOHOL IN HUMANS
Since alcohol consumption and food seeking are regulated
by overlapping neuronal mechanisms, studies sought to deter-
mine if alcohol use in humans would affect circulating ghrelin.
Several studies found that an acute low (0.55–0.6 g/kg) dose of
oral alcohol in humans decreased total and acyl-ghrelin levels
(Calissendorff et al., 2005, 2006; Zimmermann et al., 2007). In
support of these findings, active drinking AUD patients exhibited
lower plasma ghrelin levels compared with controls (Addolorato
et al., 2006; Badaoui et al., 2008). More recently, i.v. administra-
tion of alcohol was reported to reduce fasting-mediated ghrelin
levels in social drinkers (Leggio et al., 2013). Since oral alco-
hol administration greatly decreased circulating ghrelin where
i.v. administration only blunted the fasting-induced ghrelin, the
local effect of alcohol on endocrine cells in the stomach may be
an important factor in alcohol-mediated reduction of peripheral
ghrelin levels. Evidence suggests that alcohol may decrease circu-
lating ghrelin beyond a level that would be expected by the caloric
value of alcohol (Landgren et al., 2008). Furthermore, alcohol
may more specifically affect ghrelin, but not other gut peptides
like GLP-1, insulin and PPY (Calissendorff et al., 2005, 2006;
Zimmermann et al., 2007; Leggio et al., 2013).
Alcohol withdrawal appears to have the opposite effect and
increase ghrelin levels. An early study compared acyl-ghrelin
plasma levels in alcohol dependents that were abstinent for at
least 30 days, with levels in healthy controls. Abstinent individ-
uals exhibited higher levels of plasma ghrelin that were positively
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correlated with the duration of abstinence (Kim et al., 2005). In
another study, higher total plasma ghrelin levels were found after
early abstinence (at least 72 h) (Kraus et al., 2005). Another study
reported the opposite finding where baseline serum total ghrelin
levels were decreased in early abstinent individuals (72 h) rela-
tive to non-abstinent alcohol dependents (Leggio et al., 2012).
However, this may be because Kraus et al. (2005) measured ghre-
lin levels following 72 h or more after abstinence. It is possible
that plasma ghrelin levels are not clearly elevated until more than
72 h after abstinence (Kraus et al., 2005). However as previously
observed, Leggio et al. (2012) found ghrelin levels were elevated in
abstinent individuals over time. Another study has also supported
these findings by demonstrating that plasma acyl-ghrelin lev-
els slightly increased during abstinence (0–14 days) (Koopmann
et al., 2012). However, there are studies that contradict these find-
ings by showing decreased total ghrelin levels in abstinent alcohol
dependents (Wurst et al., 2007; de Timary et al., 2012). These
conflicting results may be due to differences in looking at active
acyl-ghrelin vs. total ghrelin, gender differences, sample sizes and
the time after abstinence. Together most of these data point to a
link between early alcohol withdrawal and increasing circulating
ghrelin levels. A better understanding of the factors that con-
tribute to ghrelin levels in active drinkers could potentially lead
to using plasma ghrelin as a biomarker for AUD.
There are also a number studies supporting a role for ghrelin
in alcohol craving in humans (Addolorato et al., 2006; Koopmann
et al., 2012; Leggio et al., 2012). Total plasma ghrelin levels were
positively correlated with craving as determined by the Obsessive
Compulsive Drinking Scale (OCDS) in actively drinking alco-
hol dependents (Addolorato et al., 2006). In another study, total
plasma ghrelin levels were quantified in alcohol dependents at
several time points after abstinence and compared to their craving
scores as determined by the Pennsylvania Alcohol Craving Scores
(PACS) and OCDS (Leggio et al., 2012). Total plasma ghrelin
levels quantified 72 h after abstinence were positively correlated
with PACS scores acquired after 2 weeks of abstinence, and PACS
and OCDS scores acquired after 6 and 12 weeks of abstinence.
Another study showed that plasma acyl-ghrelin levels were posi-
tively correlated with OCDS scores (Koopmann et al., 2012). The
majority of studies suggest that reducing ghrelin levels or blocking
the ghrelin receptor may reduce alcohol craving.
Lastly, there have been some genetic studies implicating ghre-
lin in alcohol dependence. One study found a SNP (rs2232165)
in exon 1 of the GHS-R1A gene to be linked with heavy alco-
hol use (Landgren et al., 2008). However, the same group
was not able to replicate an association between the same
SNP and alcohol use in a population of Caucasian females
with alcohol dependence (Landgren et al., 2010). On the other
hand, they did find weak associations between a haplotype
of the pro-ghrelin gene GHRL, and self-reported greater alco-
hol withdrawal symptoms and paternal alcohol dependence
(Landgren et al., 2010). There was also an association between
a haplotype for GHS-R1A and early-onset alcohol dependence.
These studies indicate that disruption of the ghrelin system
may predispose some individuals to AUD. Future studies will
elucidate how these haplotypes and/or SNP are linked with
AUD.
GHRELIN AND ALCOHOL IN ANIMAL MODELS
Preclinical studies have shown both normal baseline and
decreased alcohol consumption by ghrelin KO mice relative to
wildtype mice (Table 1; Jerlhag et al., 2011b; Bahi et al., 2013).
GHS-R1a KO mice also consume similar levels of alcohol relative
to wildtype mice in a limited access paradigm (Table 1; Jerlhag
et al., 2009). Compensatory effects may explain why these mice
show no difference in alcohol consumption. Other studies have
demonstrated correlations between ghrelin genes and/or levels
and alcohol-related behaviors in rodents. High alcohol preferring
AA rats exhibited increased GHS-R1a gene expression in the NAc,
VTA, amygdala, hippocampus and PFC after alcohol consump-
tion relative to non-alcohol preferring ANA rats (Landgren et al.,
2011). However, another study showed that 10 months of alcohol
consumption decreased GHS-R1a expression in the VTA of rats
(Suchankova et al., 2013). P rats and WHP rats showed greater
reductions in plasma acyl-ghrelin levels after alcohol consump-
tion relative to NP and WLP rats (Szulc et al., 2013). Together
these studies imply that alcohol affects circulating ghrelin and
central ghrelin signaling. It is possible that in the early stages
of alcohol drinking ghrelin levels may be reduced and GHS-R1a
expressionmay be increased. Longer periods of alcohol consump-
tion and withdrawal may lead to increased ghrelin and decreased
GHS-R1a expression. Future work using transgenic mice, viral-
mediated gene knockdown and different drinking paradigms will
be important to clarify the relationship between ghrelin signal-
ing in the brain and alcohol consumption. Also, since ghrelin
is expressed in the CNS, it is possible that alcohol could have
a differential effect on ghrelin levels in the corticostriatal-limbic
circuitry relative to the peripheral plasma levels.
Pharmacological studies using animal models demonstrate
the importance of ghrelin in AUD. Alcohol intake in a limited
access paradigm was increased by ghrelin administered i.c.v to
C57BL/6J mice (Jerlhag et al., 2009). GHS-R1a antagonists have
been shown to suppress alcohol consumption using several dif-
ferent paradigms (two-bottle choice, limited access, intermittent
access and fixed ratio operant self-administration) (Jerlhag et al.,
2009; Landgren et al., 2012; Bahi et al., 2013; Suchankova et al.,
2013). In terms of the brain regions involved, ghrelin increased
alcohol consumption in a limited access paradigm when admin-
istered into the VTA and into the LDTg (Jerlhag et al., 2009).
Thus, ghrelin may increase alcohol consumption by enhancing
mesolimbic dopaminergic signaling. In support of a role for ghre-
lin in reward circuitry, genetic deletion of ghrelin, GHS-R1a, or
treatment with a GHS-R1a antagonist blocked alcohol-induced
CPP (Table 1; Jerlhag et al., 2009; Bahi et al., 2013). Furthermore,
alcohol-induced dopamine release in the NAc was reduced by
GHS-R1a antagonists and blocked in GHS-R1a KO mice and
ghrelin KO mice (Jerlhag et al., 2009, 2011b). These studies
suggest that ghrelin is necessary for alcohol-induced dopamine
release in the NAc and alcohol reward, which likely contributes
to ghrelin’s effects on alcohol consumption. However, it is still
not clear if acute alcohol increases ghrelin in the VTA and if the
mechanism is local or through regulation of circulating ghrelin.
Enhanced alcohol reward sensitivity increases the risk for
binge drinking (King et al., 2011). Interestingly, a GHS-R1a
antagonist D-Lys3-GHRP-6 reduced mouse binge-like alcohol
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drinking-in-the-dark (Kaur and Ryabinin, 2010). However, it
has also been reported that peripheral administration of a dose
of ghrelin that increases food consumption did not increase
drinking-in-the-dark (Lyons et al., 2008). A recent study, sug-
gests that the discrepancy may be because circulating acylated
ghrelin does not play a significant role in alcohol consumption
and reward (Jerlhag et al., 2014). In this study, mice were admin-
istered NOX-B11-2 which binds to and neutralizes acyl-ghrelin
only in the periphery, since it cannot cross the BBB. NOX-B11-2
had no effect on alcohol-induced dopamine release, alcohol con-
sumption or alcohol-mediated CPP which implies that periph-
eral ghrelin does not play an important role in alcohol-related
behaviors. NOX-B11-2 did reduce food consumption which sup-
ports previous findings that peripheral ghrelin regulates food
intake. Thus, more work is needed to determine if periph-
eral or central ghrelin plays a greater role in regulating alcohol
consumption.
GHS-R1a antagonists have been demonstrated to attenuate
alcohol consumption, reward and reinforcement, but to be an
effective therapeutic for alcohol dependence it should prevent
relapse. A recent study implies that the GHS-R1a antagonist
JMV2959 may be useful in preventing relapse (Suchankova et al.,
2013). JMV2959 prevented the alcohol deprivation-mediated
increase in alcohol consumption in rats. It was also shown that
JMV2959 suppressed alcohol consumption of rats that had been
drinking for 8 months; tolerance did not develop to the effect and
alcohol consumption did not increase after treatment stopped
(Suchankova et al., 2013). This work, along with other pre-
clinical data, demonstrates that GHS-R1a is a promising target
for the treatment of alcohol dependence. Alternatively, GOAT
inhibitors could also be a potential therapeutic target since the
inhibition of GOAT is expected to reduce circulating acyl-ghrelin
levels.
SUMMARY
The majority of the research on ghrelin in AUD has focused on its
effects on the mesolimbic pathway and alcohol reward. GHS-R1a
antagonists appear to reduce baseline alcohol consumption by
suppressing alcohol-mediated dopamine release in the NAc and
thus alcohol reward. GHS-R1a antagonists also inhibit operant
responding for alcohol, implying that GHS-R1a antagonists sup-
press positive reinforcement for alcohol.More recently, preclinical
work has suggested that GHS-R1a antagonists may be useful for
reducing relapse and craving in AUD. The GHS-R1a antago-
nist JMV2959 was shown to reduce alcohol deprivation-mediated
increase in alcohol consumption (Suchankova et al., 2013). In
support of this finding, human studies have demonstrated posi-
tive correlations between plasma ghrelin levels and craving scores.
Therefore, GHS-R1a antagonists could potentially be used to sup-
press alcohol craving and relapse. Within corticostriatal-limbic
circuitry, the ventral hippocampus and amygdala were identi-
fied as key sites where ghrelin affects food intake (Alvarez-Crespo
et al., 2012; Kanoski et al., 2013). These two brain regions are
thought to play an important role in conditioned reinforcement
and relapse in AUD. In future work, it would be interesting to
investigate if GHS-R1a antagonists may suppress craving and pre-
vent relapse by its actions in the ventral hippocampus or the
amygdala.
SUBSTANCE P
Substance P (SP) is an 11-a.a. peptide and a member of the
tachykinin family. SP was originally isolated from the horse intes-
tine and brain (Us and Gaddum, 1931). Since its discovery, SP
has been identified in a wide range of tissues in the periph-
ery and CNS. In the CNS, SP is found in regions such as the
cortex, amygdala, hippocampus, hypothalamus, NAc, caudate,
putamen, dorsal raphe, locus coeruleus, and SN (Shults et al.,
FIGURE 5 | Regulation of alcohol consumption by substance P. (A)
Increased levels of substance P (SP) released from neurons or by
microinjection of SP into the ventral tegmental area (VTA) interacts with
neurokinin receptor 1 (NKR1) on VTA dopaminergic (DAergic) neurons
resulting in increased release of dopamine (DA) to areas like the nucleus
accumbens (NAc). Increased dopamine release in the NAc, as a result of
increased SP in the VTA, would be expected to increase alcohol
consumption since alcohol is known to disinhibit VTA dopaminergic
neurons. Alcohol is thought to inhibit GABAergic interneurons in the VTA,
which results in reduced activation of GABA receptors (GABAR) on VTA
dopaminergic neurons. (B) NK1R is also found in the ventral pallidum
(VP) and the amygdala (AMG). SP may increase administration of
rewarding substances like alcohol by increasing the excitability of neurons
in the VP and AMG.
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1984). In agreement with the expression profile of SP, it has been
implicated in mood (Santarelli et al., 2001), stress (Papp et al.,
2000), reward sensitivity (Thorsell et al., 2010), energy homeosta-
sis (Karagiannides et al., 2008), pain (Hill, 2000), and learning
(Huston and Hasenohrl, 1995).
There are three tachykinin receptor subtypes, neurokinin 1
receptor (NK1R), neurokinin 2 receptor (NK2R), and neurokinin
3 receptor (NK3R) (Severini et al., 2002). All three receptors are
G-protein-coupled receptors. SP preferentially binds to NK1R
and NK1R is expressed in many of the same brain regions as
SP (Mantyh et al., 1984; Nakaya et al., 1994). NK1R and SP
have been increasingly implicated in affective disorders. NK1R
antagonists or genetic deletion of NK1R induces anxiolytic and
antidepressant-like effects in animal models (Teixeira et al., 1996;
File, 1997; Papp et al., 2000; Rupniak et al., 2000; Santarelli et al.,
2001). There is also accumulating evidence for a role of SP/NK1R
in food intake and addiction (Murtra et al., 2000; Karagiannides
et al., 2008; Ramalho et al., 2013). A recent series of studies
suggest that NK1R antagonists have potential to be a novel thera-
peutic for AUD (George et al., 2008; Thorsell et al., 2010; Schank
et al., 2011, 2014).
SUBSTANCE P AND CORTICOSTRIATAL-LIMBIC CIRCUITRY
Inhibition or genetic deletion of NK1R has been shown to reduce
intake of natural reward and drugs of abuse (Ripley et al., 2002;
Karagiannides et al., 2008; Steensland et al., 2010; Thorsell et al.,
2010; Schank et al., 2013). One possible mechanism by which
NK1R inhibition may inhibit the administration of rewarding
substances is through modulation of mesolimbic dopaminergic
signaling. SP is found presynaptically (Tamiya et al., 1990) and
NK1R is expressed postsynaptically on dopaminergic neurons
and other neuron subtypes in the VTA (Lessard and Pickel, 2005).
Peripheral administration of SP increased dopamine in the NAc
(Boix et al., 1992) and microinjection of SP analogs into the VTA
indicate that this effect is mediated by NK1R activation in the
VTA (Figure 5A) (Elliott et al., 1986, 1991; Barnes et al., 1990).
Conversely, an NK1R antagonist was shown to reduce the number
of spontaneously active dopaminergic neurons in the VTA, fur-
ther supporting that NK1R antagonists may reduce the intake of
rewarding substances by suppressing activation of the mesolimbic
pathway (Minabe et al., 1996). SP or an SP analog in the VTA has
also increased dopamine or its metabolites in other postsynaptic
targets (e.g., PFC, amygdala) (Deutch et al., 1985; Elliott et al.,
1986; Barnes et al., 1990). Furthermore, an NK1R antagonist
reduced the number of active dopaminergic neurons in the SN,
which indicates that NK1R inhibition may also suppress the
nigrostriatal pathway (Minabe et al., 1996). Therefore, NK1R
modulation of dopamine signaling in corticostriatal-limbic cir-
cuitry could mechanistically explain the effects of the SP/NK1R
system on behaviors related to AUD.
The ventral pallidum is another important brain region for
SP/NK1R signaling. Microinjection of SP into the ventral pal-
lidum induces CPP and this effect is inhibited by a NK1R antag-
onist (Nikolaus et al., 1999). The ventral pallidum receives input
from the cortex, amygdala, NAc, and other areas that express SP
(Reep andWinans, 1982; Napier et al., 1995; Mitrovic and Napier,
1998). An analog of SP increased the excitability of the ventral
pallidum which is interesting since inactivation of the ventral pal-
lidum is thought to prevent drug- or stress-induced reinstatement
(Napier et al., 1995; McFarland and Kalivas, 2001; McFarland
et al., 2004). Therefore, NK1R antagonists may reduce addictive
behaviors through suppressing activity of the ventral pallidum
(Figure 5B).
SP may also regulate addictive behaviors through affecting
neurotransmission in the amygdala. The rewarding effects of
morphine were suppressed by lesioning NK1R-expressing cells in
the amygdala (Gadd et al., 2003). Besides regulating the reward-
ing effects of substances, inhibition of NK1R in the amygdala may
reduce stress-induced relapse or negative affect associated with
AUD. Microinjection of a SP receptor antagonist into the amyg-
dala was anxiolytic, where SP was anxiogenic (Ebner et al., 2004;
Zhao et al., 2009). Furthermore, emotional stressors increased SP
in the amygdala (Ebner et al., 2004). Thus, inhibiting amygdala SP
signaling may reduce the effects of stress and anxiety on promot-
ing addictive behaviors (Figure 5B). Actually, a NK1R antagonist
was shown to suppress stress-induced reinstatement for cocaine
and we will discuss below how NK1R antagonists are promising
therapeutics for the prevention of stress-induced relapse in AUD
(Schank et al., 2014).
SUBSTANCE P AND ALCOHOL IN HUMANS
The importance of SP/NK1R system in AUD is supported by the
observation of significant associations between the NK1R gene
(TACR1; rs6715729 and two haplotypes) and alcohol dependence
(Seneviratne et al., 2009). TACR1 SNPs (rs3771863, rs3755459,
and rs1106855) were also associated with blood oxygen level
dependent (BOLD) responses to the taste of alcohol in the medial
PFC, putamen and insula, as measured by fMRI in heavy drinkers
(Blaine et al., 2013). This implies that the SP/NK1R system
may regulate alcohol-related behaviors by acting on circuitry
in the cortex and dorsal striatum in humans. The same study
also reported associations between TACR1 SNPs (rs10490308,
rs11688000, rs3771863) and symptoms of alcohol dependence.
Clinical studies suggest that NK1R antagonists may be useful
for suppressing stress-induced craving for alcohol. A randomized
controlled study observed that detoxified patients with AUD who
were given NK1R antagonist, LY686017, showed improved crav-
ing control, wellbeing, and stress response after social stress test or
alcohol-cue challenge compared to placebo counterparts (George
et al., 2008). By measuring BOLD activity by fMRI, LY686017
was found to suppress increased reactivity to negative emotional
stimuli and enhance responses to positive emotional stimuli that
were blunted in alcohol dependents (George et al., 2008). In addi-
tion, LY686017 reduced activation of the insula, which is involved
in craving and addictive behavior (George et al., 2008; Naqvi
and Bechara, 2009). The fact that LY686017 reduced stress-related
craving and normalized responses to emotional stimuli, suggests
the effect of NK1R antagonists on stress-related circuitry may be
an importantmechanism behind their therapeutic effect. Another
clinical study examining the efficacy of NK1R antagonist, aprepi-
tant, as a treatment for PTSD comorbid with alcohol dependence
did not observe any treatment effect on PTSD symptoms and
subjective and physiological responses to stress or alcohol cues,
but fMRI showed a robust potentiation in the ventromedial PFC,
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suggesting that NK1R antagonism may be beneficial for alcoholic
patients with PTSD to some extent (Kwako et al., 2014).
SUBSTANCE P AND ALCOHOL IN ANIMAL MODELS
Animal studies point to an association between disruption of
SP/NK1R signaling and increased risk for alcohol-related prob-
lems. For example, SP immunoreactivity or expression is reduced
in the frontal cortex and central nucleus of the amygdala (CeA)
of alcohol-naïve P rats relative to NP rats (Slawecki et al., 2001;
Yang et al., 2009). As a possible compensatory effect, P rats exhib-
ited elevated expression of NK1R and receptor binding in the CeA
(Schank et al., 2013). The TACR1 SNP, -1372G/C, was found to
affect TACR1 expression, where presence of the C-allele was asso-
ciated with increased TACR1 expression (Schank et al., 2013). All
P rats, compared to only 18% of the Wistar rats, were homozy-
gous for the C-allele, which may explain the increased amygdala
NK1R expression in P rats (Schank et al., 2013). These results sug-
gest that dysregulated SP/NK1R signaling may increase the risk
for developing AUD. Conversely, alcohol may disrupt SP signal-
ing, which could facilitate the development of AUD since chronic
alcohol exposure increased SP immunoreactivity in the caudate
and decreased SP immunoreactivity in the frontal cortex of rats
(Slawecki et al., 2005).
Preclinical studies have demonstrated that disruption of
SP/NK1R signaling alters alcohol-related behaviors in rodents.
Genetic deletion of NK1R in mice reduced two-bottle choice
alcohol consumption, increased alcohol-mediated sedation, and
attenuated alcohol reward relative to wildtype mice (Table 1;
George et al., 2008; Thorsell et al., 2010). Furthermore, NK1R
KO mice showed reduced alcohol consumption in an escalated
drinking model which involved intermittent access to 15% alco-
hol (Thorsell et al., 2010). NK1R antagonists had a similar
effect and reduced two-bottle choice drinking and operant self-
administration of alcohol in mice and rats (Steensland et al.,
2010; Thorsell et al., 2010; Schank et al., 2013). However, the
NK1R antagonist ezlopitant had no effect on the breakpoint
for alcohol in a progressive ratio operant responding schedule
and more effectively reduced sucrose self-administration in Long
Evans rats (Steensland et al., 2010). This suggests that ezlopitant
non-specifically reduces reward sensitivity at the dose required
to decrease responding for alcohol consumption and does not
potently suppress motivation to seek alcohol. However, another
study showed that the NK1R antagonist L822429 reduced pro-
gressive ratio responding for alcohol by P rats, but not by Wistar
rats (Schank et al., 2013). L822429 did not reduce saccharine
intake like ezlopitant (Schank et al., 2013). Thus, it is possible
that NK1R antagonists may be specifically beneficial for attenu-
ating alcohol seeking in those with a disrupted SP/NK1R system.
Also, P rats have been shown to exhibit an anxiety-like phenotype
and may be more sensitive to the effect of NK1R antagonists on
reducing negative reinforcement for alcohol (Stewart et al., 1993).
There is some evidence that the amygdala may be a target
for the therapeutic effect of NK1R antagonists. Intra-amygdala
infusion of the NK1R antagonist L822429 reduced alcohol self-
administration in P rats while injections in the PFC did not
(Schank et al., 2013). The amygdala is a component of the
extended stress system, thus may play an important role in
motivating drug seeking (reviewed by Schank, 2014). In fact,
some preclinical studies indicate that NK1R antagonists may
suppress stress-mediated alcohol relapse. The NK1R antagonist
L822429 blocked footshock stress-induced reinstatement for alco-
hol seeking in Long Evans rats (Schank et al., 2011). L822429 also
suppressed yohimbine (pharmacological stressor)-induced rein-
statement of alcohol seeking at a dose that did not affect alcohol or
saccharine administration, suggesting that stress-induced alcohol
reinstatement is especially sensitive to NK1R antagonists (Schank
et al., 2014). It is possible that NK1R antagonists reduce alco-
hol intake by multiple mechanisms, which involve both positive
reinforcement and negative reinforcement for alcohol.
SUMMARY
Preclinical studies have demonstrated SP/NK1R system’s involve-
ment in regulating voluntary alcohol administration, but more
studies on the SP/NK1R signaling among corticostriatal-limbic
structures is still needed to ascertain the areas of action and
their interconnections for the specific effects elicited, such as
stress relief and reduced motivation to seek alcohol. Both pre-
clinical and clinical studies support that NK1R antagonism could
be a potential treatment for reducing alcohol consumption, pos-
sibly through craving reduction and stress response alleviation.
However, there is still a lack of clinical evidence for NK1R antag-
onist efficacy in reducing alcohol consumption or improving
abstinence length. Future studies need to be conducted to confirm
the usefulness of these antagonists in abstinence maintenance and
to determine the specific alcohol dependent patients who will
benefit most from them such as those with comorbid PTSD.
NPY
NPY is a 36-a.a. neurotransmitter that is widely distributed in
both the central and peripheral nervous system (Tatemoto et al.,
1982; Gray andMorley, 1986). Thus, NPY influences a wide range
of physiologic functions. NPY is best known for its orexigenic
and anxiolytic properties (Badia-Elder et al., 2007). There are five
G-protein-coupled NPY receptor subtypes: Y1R, Y2R, Y4R, Y5R,
and Y6R (Blomqvist and Herzog, 1997). Y1R is mainly expressed
postsynaptically and is activated by full-length NPY (Sheikh et al.,
1989; Widdowson, 1993; Gehlert and Gackenheimer, 1997). In
the CNS, Y1R is expressed in several brain regions including
the cerebral cortex, striatum, amygdala, hypothalamus, thalamus,
hippocampus and the nucleus of the solitary tract (Wolak et al.,
2003). In contrast, Y2R is mainly located presynaptically and
can be activated by C-terminal fragments of NPY (Widdowson,
1993; Gerald et al., 1995; Gehlert and Gackenheimer, 1997).
Presynaptically, Y2R acts as an autoreceptor on NPY terminals
and inhibits the release of endogenous NPYwhen activated (Chen
et al., 1997; King et al., 1999), thus inhibition of Y2R would
result in similar behavioral effects as Y1R-stimulation. Y2R also
regulates the release of other neurotransmitters like GABA and
glutamate (Greber et al., 1994; Sun et al., 2001). Y2R is widely
expressed in multiple brain regions such as the amygdala, hip-
pocampus, cortex, thalamus, lateral septum, olfactory nuclei and
striatum (Caberlotto et al., 1998; Stanic et al., 2006). Y5R is
found in areas such as the cerebral cortex, striatum, hypotha-
lamus, thalamus and hippocampus (Wolak et al., 2003). Both
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FIGURE 6 | NPY signaling in the amygdala and alcohol consumption.
Neuropeptide Y (NPY) receptor type 1 (Y1R) agonists and NPY receptor
type 2 (Y2R) antagonists in the central amygdala (CeA) may reduce alcohol
consumption through mimicking the effects of acute alcohol on GABAergic
signaling. Both receptors are thought to be inhibitory, but differ in their
location. Y2R may be predominantly on presynaptic GABAergic
interneurons, where Y1R may be expressed postsynaptically on GABAergic
output neurons. Therefore, inhibiting Y2R function would increase GABA
release from GABAergic interneurons in the CeA, similar to alcohol which is
known to facilitate GABAergic signaling in the amygdala. Increased
activation of GABA receptors (GABAR) in the CeA would reduce CeA
output. Activating Y1R would also inhibit postsynaptic CeA neurons similar
to increasing GABAergic signaling. Furthermore, Y2R antagonists would be
expected to increase NPY which would facilitate the effect at Y1R.
Decreased CeA output has been linked with reduced anxiety which is
hypothesized to suppress stress-induced alcohol relapse.
Y5R and Y1R have been implicated in the orexigenic effects of
NPY (Gerald et al., 1996; Nguyen et al., 2012). Y1R, Y2R, and
Y5R have been implicated in the anxiolytic action of NPY (Heilig
et al., 1993; Tschenett et al., 2003; Sorensen et al., 2004). Y4R
is predominantly expressed in the peripheral tissues (Parker and
Herzog, 1999). Y6R is a non-functional receptor in most mam-
mals (Matsumoto et al., 1996). Research on Y4R and Y6R is much
less extensive and will not be discussed in this review.
NPY AND CORTICOSTRIATAL-LIMBIC CIRCUITRY
Most research on the mechanisms behind the behavioral effects
of NPY have been focused on the actions of NPY in the amyg-
dala since NPY is anxiolytic. The extended amygdala consists
of the CeA, the bed nucleus of the stria terminalis, and NAc
shell. NPY administration i.c.v or into the CeA is anxiolytic in
Table 1 | Alcohol consumption and alcohol reward behavior in
gut-brain peptide mouse models.
Neuropeptide Mouse Alcohol Alcohol References
consumption CPP
Neurotensin NTS1 KO ↑ ND Lee et al., 2010
NTS2 KO ↑ ND Lee et al., 2011
NT KO ND ND
GLP-1 GLP-1 KO ND ND
GLP-1R KO ND ND
Ghrelin ghrelin KO ↓/– ↓ Jerlhag et al.,
2011b; Bahi et al.,
2013
GHS-R1a KO – ↓ Jerlhag et al.,
2009
SP NK1R KO ↓ ↓ George et al.,
2008; Thorsell
et al., 2010
NPY NPY KO ↑ ND Thiele et al., 1998
NPY OVREXP ↓ ND Thiele et al., 1998
Y1R KO ↑ ND Thiele et al., 2002
Y2R KO ↓ ND Thiele et al., 2004
Y5R KO – ND Thiele et al., 2000
Abbreviations and symbols: ND, no data; ↓, decrease; ↑, increase; –, no change;
OVREXP, overexpression.
rodents (Heilig et al., 1993). The anxiolytic effect in the amyg-
dala may be mediated by Y1R or Y2R since microinjection of
an Y1R agonist and deletion of Y2R in the CeA is anxiolytic
(Heilig et al., 1993; Tasan et al., 2010). Thus, Y1R and Y2R appear
to have opposite effects on anxiety which can be explained by
their receptor localization. Y2R is primarily found presynapti-
cally where it acts as an autoreceptor to inhibit the release of
NPY, so antagonism of the receptor would theoretically pro-
mote postsynaptic NPY signaling (Chen et al., 1997; King et al.,
1999). NPY colocalizes with GABAergic fibers in the CeA and
the output neurons of the CeA are mainly GABAergic MSNs
(McDonald and Pearson, 1989). Increased activation of the CeA
output neurons seems to be associated with increased fear-related
behavior (Mohler, 2012). Y1R and Y2R are both coupled to
inhibitory G-proteins (Michel, 1991). Thus, activation of Y1R on
postsynaptic CeA MSNs and inhibition of presynaptic Y2R on
GABAergic terminals could theoretically inhibit the output of the
CeA and reduce anxiety (Gilpin et al., 2011). The effects of NPY
on CeA activity may also affect behaviors related to AUD since
lesioning the CeA reduces alcohol consumption (Moller et al.,
1997). It is theorized that acute alcohol increases GABA trans-
mission in the CeA which reduces anxiety, but chronic alcohol
may have the opposite effect (Kang-Park et al., 2013). Thus, an
Y1R agonist and an Y2R antagonist would be expected to have
similar anxiolytic effects as acute alcohol in the CeA (Figure 6).
The extended amygdala also plays an important role in alco-
hol reinforcement and reinstatement, so NPY may affect other
alcohol-related behaviors through its actions in the amygdala.
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Here we will discuss how NPY, especially in the CeA, may reduce
alcohol consumption.
NPY AND ALCOHOL IN HUMANS
A number of human genetic studies have implicated NPY-related
genes in AUD. One of the largest studies identified associa-
tions between SNPs in the NPY2 and NPY5 receptor genes with
alcohol withdrawal symptoms (Wetherill et al., 2008). Other stud-
ies have identified SNPs in NPY to be associated with alcohol
dependence or higher levels of alcohol consumption (Karvonen
et al., 1998; Lappalainen et al., 2002; Bhaskar et al., 2013). In
humans, a microarray study using postmortem tissue showed that
NPY expression was reduced in the frontal and motor cortices
of chronic alcohol drinkers relative to controls (Mayfield et al.,
2002).These studies suggest that a disruption in NPY signaling
may increase the risk for developing AUD in humans.
NPY AND ALCOHOL IN ANIMAL MODELS
Research with alcohol-preferring rat strains suggests that NPY
signaling may play an essential role in their alcohol-related behav-
iors. In two different alcohol preferring rat strains, P rats and
HAD rats, baseline NPY levels were lower in the amygdala com-
pared to control rats, suggesting that reduced NPY in the amyg-
dala may promote increased alcohol intake (Ehlers et al., 1998;
Hwang et al., 1999). Consistently, genetic linkage studies of P and
NP rats identified a QTL on chromosome 4 that was linked to dif-
ferences alcohol consumption levels and included the NPY gene
(Carr et al., 1998). Later, congenic strains created from inbreed-
ing P and NP lines of rats confirmed that the identified QTL
from P rats partially explained their increased alcohol consump-
tion and reduced NPY levels (Carr et al., 2006; Liang et al., 2010).
These studies suggest that NPY signaling regulates alcohol-related
behaviors, especially in the amygdala and cortex.
Conversely, alcohol can affect brain NPY levels. Repeated alco-
hol consumption or exposure has been shown to decrease NPY
in the cortex, amygdala or hypothalamus (Roy and Pandey, 2002;
Walker et al., 2010; Sparrow et al., 2012). Another study demon-
strated that acute alcohol administration (1 g/kg) or 9 days of
voluntary alcohol consumption increased NPY levels in the cen-
tral and medial amygdala in P rats, but not NP rats (Pandey
et al., 2005). In the same study, cAMP response element-binding
protein (CREB) activity was quantified since NPY is a CREB-
regulated gene. Both alcohol treatments increased CREB activity
in P rats, which suggests that acute alcohol-induced increase in
NPYmay be due to alcohol-mediated activation of CREB (Pandey
et al., 2005). One hypothesis that could be formed from these
studies is that low doses of alcohol may be consumed to increase
NPY to baseline levels. Decreased NPY in the amygdala may result
from genetic differences or alcohol withdrawal. Reduced amyg-
dala NPY has been linked to increased anxiety (Pandey et al.,
2005) and since low doses of alcohol may increase NPY, alcohol-
induced NPY expression may be a possible mechanism for the
anxiolytic effect of alcohol.
Animal studies indicate that reduced NPY signaling enhances
alcohol consumption. For example, NPY KO mice consumed
more alcohol and NPY overexpression lowered alcohol consump-
tion relative to wildtype mice in a two-bottle choice drinking
paradigm (Table 1; Thiele et al., 1998). Also, NPY KO mice were
less sensitive and NPY overexpressing mice were more sensitive
to the sedative effects of alcohol, suggesting that decreased NPY
signaling increases tolerance to alcohol intoxication, which could
increase drinking (Thiele et al., 1998). Moreover, Y1R KO mice
consumedmore alcohol, whereas Y2R KOmice drank less alcohol
than wildtype controls in a two-bottle choice paradigm (Table 1;
Thiele et al., 2002, 2004). The opposing effects of these receptors
probably reflect the function of Y2R as a presynaptic autoreceptor.
Y5R KOmice appear to drink similar amounts of alcohol as wild-
type mice, suggesting that Y5R does not may a major role in AUD
(Table 1; Thiele et al., 2000). Pharmacological studies have shown
that NPY reduces alcohol consumption, but NPY appears to be
effective only in alcohol-preferring rodents or alcohol-exposed
animals. For example, i.c.v. administration of NPY reduced alco-
hol intake in a 2 h limited access paradigm in P and HAD rats, but
not in NP, LAD or Wistar rats (Badia-Elder et al., 2001, 2003).
Central administration of NPY also reduced alcohol drinking-
in-the-dark by alcohol-preferring C57BL/6J mice (Sparrow et al.,
2012). Other studies showed that i.c.v. administration of NPY
reduced alcohol consumption (in a limited access and sipper tube
operant administration paradigm) in Wistar rats that were previ-
ously exposed to alcohol vapor (Thorsell et al., 2005a,b). Another
study demonstrated that i.c.v. administered NPY more effectively
reduced alcohol consumption in P rats that have undergone a
period of withdrawal (Gilpin et al., 2003). These latter studies
suggest that NPY may reduce drinking by suppressing negative
reinforcement for alcohol. Similar results have been obtained with
drugs targeting NPY receptors. The Y2R antagonist BIIE0246
suppressed alcohol self-administration in Wistar rats that had
been previously exposed to ethanol vapor (Rimondini et al.,
2005). In another study, an Y1R agonist and Y2R antagonist
reduced alcohol drinking-in-the-dark in C57BL/6Jmice (Sparrow
et al., 2012). Interestingly, systemic administration of an Y2R
antagonist was shown to reverse increases in anxiety-like behav-
ior after alcohol withdrawal, again implying that NPY signaling
may regulate negative reinforcement (Cippitelli et al., 2011). Y5R
antagonists have been shown to decrease or to have no effect on
alcohol self-administration which supports the previous finding
that genetic deletion of Y5R does not alter alcohol drinking in
mice (Thiele et al., 2000; Schroeder et al., 2003, 2005).
Pharmacological and genetic studies suggest that NPY sig-
naling in the amygdala may be a key mechanism behind the
anti-drinking effects of NPY. NPY infusions into the CeA reduced
alcohol self-administration in Wistar rats that had been on an
alcohol-containing diet, but had no effect in rats that were on
an isocaloric diet (non-dependent rats; Gilpin et al., 2008). CeA
NPY also reduced two-bottle choice alcohol consumption in P
rats that had been previously consuming alcohol (Pandey et al.,
2005). Furthermore, viral-mediated overexpression of NPY in
the CeA decreased alcohol drinking specifically in anxious Long
Evans rats (Primeaux et al., 2006). These studies imply that
chronic alcohol exposure or heightened anxiety may increase
sensitivity to the anti-drinking effects of NPY in the CeA. The
effect of NPY in the CeA on alcohol drinking is likely mediated
by its actions on Y2R or Y1R. There is some evidence that NPY
acts on presynaptic Y2R in the CeA and inhibits alcohol mediated
increases in GABAergic transmission, however this mechanism
is controversial since systemic administration of Y2R antagonists
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reduce alcohol consumption in rodents (Roberto et al., 2003;
Gilpin et al., 2011).Thus, further work is necessary to elucidate
the actions of NPY and alcohol in the amygdala.
SUMMARY
Preclinical studies indicate that reduced NPY signaling, espe-
cially in the CeA, may increase susceptibility for developing AUD.
Therefore, Y1R agonists and Y2R antagonists (since Y2R acts as an
autoreceptor) seem promising for the treatment of heavy drinking
that is driven by anxiety or negative reinforcement. However, very
little is known about the mechanism behind the anti-drinking
effects of Y1R agonists and Y2R antagonists. Microinjection of
Y1R or Y2R-selective pharmacological agents into the amygdala
has yielded conflicting results in regard to alcohol consump-
tion. Considering that Y1R and Y2R are expressed in other
brain regions within corticostriatal-limbic circuitry, more work is
needed to determine the mechanism behind the therapeutic effect
of these drugs.
DISCUSSION AND FUTURE DIRECTION
Accumulating preclinical and early clinical work suggests that
drugs targeting gut-brain peptide signaling are promising ther-
apeutics for the treatment of AUD. Before moving drugs into
clinical trials, however, it is essential to validate the therapeu-
tic potential in humans through in-depth behavioral tests and
translational research, which includes pharmacodynamic and
pharmacokinetic studies in larger animal models. The gut-brain
peptides highlighted in this review so far appear to effectively
reduce particular addictive behaviors. AUD is a complex hetero-
geneous disorder. There are numerous reasons why people begin
drinking and why they cannot control their use. Comorbid psy-
chiatric and neurological disorders, such as anxiety or chronic
pain, may increase propensity to drink and promote relapse.
Here, we discussed evidence for why drugs targeting SP and
NPY may be useful for the treatment of alcohol dependence with
comorbid anxiety. NTS2 or NTS1 agonists may be useful for
treating alcohol dependence with comorbid pain-related prob-
lems or psychosis. GHS-R1a antagonists have been implicated in
alcohol craving, while GLP-1R agonists may be particularly effec-
tive in heavy drinkers. For future studies, it will be important to
identify subgroups of individuals with AUD that would receive
the most benefit and least side effects from potential peptide
therapeutics for AUD. Although a daunting task, individualized
treatment for AUD seems to be the next frontier for the field.
The identification of biomarkers and longitudinal studies will
help to demonstrate whether these peptides play a major role
in AUD.
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